The molecular pathogenesis of BCR::ABL-negative myeloproliferative neoplasms was unascertained until 2005, when the presence of an activating point mutation in the JAK2 gene was first described [12,13,14,15]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.